Arrowhead Pharma is squaring up to rival Ionis in the severe hypertriglyceridaemia (sHTG) market, trumpeting new data for its ...

An oral relaxin agonist developed by AstraZeneca, codenamed AZD5462, has been shown to improve cardiac function in patients ...

Takeda and Protagonist Therapeutics' hepcidin mimetic rusfertide has been approved by the FDA to treat polycythaemia vera (PV ...

Cytokinetics has revealed the highly anticipated data from the ACACIA-HCM study of Myqorzo, which promises to take the cardiac myosin inhibitor into new territory for the class. First teased in May, ...

Through increased government investment in AI and in silico technologies, and prominent partnerships and milestones from companies like 1st Biotherapeutics, Galux, Hanmi Pharm, and LG Research AI, ...

South Korea’s mRNA ecosystem is rapidly advancing, fueled by progress from companies like GC Biopharma and EyeGene in ...

The new acquisition is Lilly's ninth since the start of the year, coming just a few weeks after it agreed to buy psychedelic ...

A new, universal definition for a heart attack or myocardial infarction (MI) recognises that there are many different ...

Since 2001, International Overdose Day has been observed as a moment to remember those lost to overdose and renew society’s ...

Since taking effect in August 2024, the EU AI Act (Regulation (EU) 2024/1689) has categorised AI tools by risk level. For ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results with a ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in non-muscle invasive bladder cancer (NMIBC). Top-line results from the ...